The prophylaxis and treatment of antiphospholipid syndrome – current options, difficulties and future perspectives

1. Giannakopoulos B, Passam F, Ioannou Y et al. How we diagnose the antiphospholipid syndrome. Blood 2009; 113: 985–994.

2. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on update of an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.

3. Galli M, Reber G, de Moerloose P et al. Invitation to a debate on the serological criteria that define the antiphopsholipid syndrome. J Thromb Haemost 2008; 6: 399–401.

4. Swadźba J, Iwaniec T, Szczeklik A et al. Revised classification criteria for antiphospholipid syndrome and the thrombotic risk in patients with autoimmune disease. J Thromb Haemost 2007; 5: 1883–1889.

5. Swadźba J, Musial J. Letters to the Editor. More on: The debate on antiphospholipid syndrome classification criteria. J Thromb Haemost 2009; 7: 501–502.

6. Ruffatti A, Olivieri S, Tonello M et al. Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost 2008; 6: 1693–1696.

7. Ruffatti A, Pengo V. Antipospholipid syndrome classification criteria: comments to the Letter of Jakub Swadźba and Jacek Musial. J Thromb Haemost 2009; 7: 503–504.

8. Tripodi A. More on: criteria to define the antiphospholipid syndrome. J Thromb Haemost 2008; 6: 1049–1050.

9. Buliková A, Zavřelová J, Penka M. Antifosfolipidový syndrom v roce 2009. Vnitř Lék 2009; 55: 253–262.

10. Erkan D, Lockshin MD. Antiphospholipid syndrome. Curr Opin Rheumatol 2006; 18: 242–248.

11. Cohen HM, Machin SJ. Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants? Lupus 2010; 19: 486–491.

12. Branch DW, Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet Gynecol 2003; 101: 1333–1344.

13. Manganelli R, Innaccone S, Manganelli S et al. Update on antiphospholipid syndrome management. In: Buliková A (ed.). Antiphospholipid syndrome. Rieka: Intech 2012: 175–196.

14. Merjian A, Lim W. ASH evidence-based guide­lines: should asymptomatic patients with antiphosholipid antibodies receive primary prophylaxis to prevent thromobosis? Hematology Am Soc Hematol Educ Program 2009; 247–249.

15. Keeling D, Mackie I, Moore GW et al. British Committee for standards in haematology. Guide­lines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012; 157: 47–58.

16. Erkan D, Harrison MJ, Levy R et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double--blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007; 56: 2982–2391.

17. Tarr T, Lakos G, Bhattoa HP et al. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus 2007; 16: 39–45.

18. Pengo V, Ruffatti A, Legnani C et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8: 237–242.

19. Cuadrado MJ, Mujic F, Muñoz E et al. Thrombocytopenia in the antiphospholipid syndrome. Ann Rheum Dis 1997; 56: 194–196.

20. Finazzi G. The Italian registry of antiphospholipid antibodies. Haematologica 1997; 82: 101–105.

21. Trenfield S, Parmar K, Hunt BJ. Monitoring heparin in patients with a lupus anticoagulant: detection of heparin resistance. J Thromb Haemost 2008; 6: 1980–1982.

22. Buliková A. Trombocytopenie u pacientů s průkazem antifosfolipidových protilátek nebo s antifosfolipidovým syndromem. Vntiř Lék 2010; 56 (Suppl 1): S81–S90.

23. Arnout J. The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelisms with heparin-induces thrombocytopenia. Thromb Haemost 1996; 75: 536–541.

24. Gruel Y, Rupin A, Watier H et al. Anticardio­lipin antibodies in heparin-associated thrombocytopenia. Thromb Res 1992; 67: 601–606.

25. Socher I, Kroll H, Jorsk S et al. Heparin-independent activation of platelet by heparin-induced thrombocytopenia antibodies: a common occurrence. J Throm Haemost 2008; 6: 197–200.

26. Pauzner R, Greinacher A, Selleng K et al. False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Tromb Haemost 2009; 7: 1070–1074.

27. Martion-Toutain I, Piette JC, Diemert MC et al. High prevalence of antibodies to platelet factor 4 heparin in patients with antiphospholipid antibodies in absence of heparin induced thrombocytopenia. Lupus 2007; 16: 79–83.

28. Lo GK, Sigouin CS, Warkentin TE. What is the potential overdiagnosis of heparin-induced thrombocytopenia. Am J Hematol 2007; 82: 1037–1043.

29. Warkentin TE. Antiphospholipid and anti-PF4 antibodies: an association affecting anti-PF4/heparin assay analysis. J Throm Haemost 2009; 7: 1067–1069.

30. Greinacher A. Heparin-Induced thrombocytopenia. J Thromb Haemost 2009; 7 (Suppl 1): 9–12.

31. Lo GK, Juhl D, Warkentin TE et al. Evaluation of pretest clinical score (4T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4: 759–765.

32. Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic events in 70 patients. Ann Inter Med 1992; 117: 303–308.

33. Khamashta MA, Curado MJ, Mujic F et al. The management of thrombosis in the antiphospholipid syndrome. N Engl J Med 1995; 332: 993–997.

34. Crowther MA, Ginsberg JS, Julian J et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133–1138.

35. Finazzi G, Marchioli R, Brancaccio V et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patient with antiphospholipid antibody synd­-rome (WAPS). J Thromb Hemost 2005; 3: 848–853.

36. Ames PR, Ciampa A, Margaglione M et al. Bleeding and re-thrombosis in primary antiphospholipid syndrome on oral anticoagulation. An 8-year longitudinal comparison with mitral valve replacement and inherited thrombophilia. Thromb Haemost 2005; 93: 694–699.

37. Wittkowsky AK, Downing J, Blackburn J et al. Warfarin-relatied outcomes in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic. Thromb Haemost 2006; 96: 137–141.

38. Kearon C, Julian JA, Kovacs MJ et al. ELATE investigators. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood 2008; 112: 4432–4436.

39. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid syndrome. A systematic review. JAMA 2006; 295: 1050–1057.

40. Giannakopoulos B, Krilis SA. How I treat the antiphospholipid syndrome. Blood 2009; 114: 2020–2030.

41. Kearon C, Akl AE, Comerota AJ et al. American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9^th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e419S–e494S.

42. Schulman S, Svenungsson E, Granvist S. Duration of anticoagulation study group. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among pa­tients with venous thromboembolism following anticoagulant therapy. Am J Med 1998; 104: 332–338.

43. Büller HR, Agnelli G, Hull RD et al. Antithrombotic Therapy for venous thromboembolic disease: the Seventh ACCP Conference onAnti­thrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl): 401S–428S.

44. Lawrie AS, Purdy G, Mackie IJ et al. Monitoring of oral anticoagulant therapy in lupus anticoagulant positive patients with the anti-phospholipid syndrome. Br J Haematol 1997; 98: 887–892.

45. Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997; 127: 177–185.

46. Arnout J, Vermylen J. Lupus anticoagulant: Influence on the International normalized ratio. Thromb Haemost 1999; 81: 847–849.

47. Robert A, Le Querrec A, Delahousse B et al. Control of oral anticoagulation in patients with the antiphospholipid syndrome – influence of the lupus anticoagulant on International normalized ratio. Groupe Méthodologie en Hémostase du Groupe d’Etudes sur l’Hémostases et la Thrombose. Tromb Haemost 1998; 80: 99–103.

48. Tripodi A, Chantarangkul V, Clerici M et al. Laboratory control of oral anticoagulant treatment by the INR system in patients with the anti­phospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercials thromboplastins. Br J Haematol 2001; 115: 672–678.

49. Carrasco C, Campbell B, Shiach C. Effects of the lupus anticoagulants on the control of oral anticoagulant treatment. Br J Haematol 2004; 124: 555–563.

50. Buliková A, Némethová D, Penka M et al. Ovlivňuje přítomnost lupus antikoagulans antikoagulační léčbu u pacientů s antifosfolipidovým syndromem? Transfuze Hematol dnes 2005; 11: 148–153.

51. Khamashta MA. Management of thrombosis in the antiphospholipid syndrome. In: Khamashta MA (ed.). Hughes Syndrome. London: Springer-Verlag 2000: 391–396.

52. Levine SR, Brey RL, Tilley BC et al. APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patient with ischemic stroke. JAMA 2004; 291: 576–584.

53. Okuma H, Kitagawa Y, Yasuda T et al. Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int J Med Sci 2009; 7: 15–18.

54. Lansberg MG, O’Donnell MJ, Khatri P et al. American College of Chest Physicians. Antithrombotic a thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9^th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e601S–e636S.

55. Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systemic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheumatism 2007; 57: 1487–1495.

56. Buliková A, Penka M. Selhání antikoagulační léčby. Vnitř Lék 2006; 52 (Suppl 1): 107–118.

57. Dentali F, Manfredi E, Crowther M et al. Long-duration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy. J Thromb Haemost 2005; 3: 2121–2123.

58. Statkute L, Traynor A, Oyama Y et al. Anti­phospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantation. Blood 2005; 106: 2700–2709.

59. Cervera R, Piette JC, Font J et al. Antiphospholipid syndrome: clinical and immunological manifestations and patterns of disease expresion in a cohort of 1,000 patients. Arthritis Rheumat 2002; 46: 1019–1927.

60. Vora SK, Aherson RA, Erkan D. Catastrophic antiphospholipid syndrome. J Intensive Care 2006; 21: 144–159.

61. Erkan D, Lockshin MD. Non-criteria manifestation of antiphospholipid syndrome. Lupus 2010; 19: 424–427.

62. Caraba A, Crisan V, Munteanu A et al. The kidney in antiphospholipid syndrome. In: Bulikova A (ed.). Antiphospholipid syndrome. Rieka: Intech 2012: 125–138.

63. Buliková A, Penka M. Antifosfolipidový syndrom – diagnostika a léčba. Vnitř Lék 2005; 51: 809–817.

64. Korkmaz G, Kabukcuoğlu S, Isiksoy S et al. Renal involvement in primary antiphospholipid syndrome and its response to immunosuppressive therapy. Lupus 2003; 12: 760–765.

65. Espinosa-Zavaleta N, Montes RM, Soto ME et al. Primary antiphospholipid syndrome: a 5-year transesophageal echocardiographic follow up study. Am Heart J 1999; 137: 974–979.

66. Atsumi T, Furukawa S, Amengual O et al. Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. Lupus 2005; 14: 499–504.

67. Opatrny L, David M, Kahn SR et al. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol 2006; 33: 2214–2221.

68. Bates SM, Geer IA, Middeldrop S et al. American College of Chest Physicians. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl); e691S–e736S.

69. Empson M, Lassere M, Craig J et al. Prevention of recurrent miscarriage for women with antiphospholipid antibodies or lupus anticoagulant. Cochrane Database Syst Rev 2005; CD002859.DOI: 10.1002/14651858.CD002859.pub2.

70. Clark CA, Spitzer KA, Crowther MA et al. Incidence of postpartum thrombosis and preterm delivery in women with antiphospholipid antibodies and recurrent pregnancy loss. J Rheumatol 2007; 34: 992–996.

71. Branch DW, Silver RM, Porter TF. Obstetric antiphospholipid syndrome: current uncertainties should guide our way. Lupus 2010; 19: 446–452.

72. Segovia AG, Rodríquez-Mahou M, Caballero P et al. Antiphospholipid antibodies in women with recurrent gestational failure – controversies in management. In: Buliková A (ed.). Antiphospholipid syndrome. Rieka: Intech 2012; 151–160.

73. Parravacini V, Caserta S. The immunomodulatory roles of vitamin D3: New tricks for an old dog. Mol Interv 2010; 10: 204–208.

74. Rotar Z, Rozman B, de Groot PG et al. Sixth meeting of the European forum on antiphospholipid antibodies. How to improve the understanding of the antiphospholipid syndrome. Lupus 2009; 18: 53–60.

75. Pierangeli SS, Erkan D. Antiphopholipid syndrome treatment beyond anticoagulation: are we there yet? Lupus 2010; 19: 475–485.

76. Murthy V, Erkan D, Jajoria P et al. Effects of Fluvastatin on Pro-Inflammatory and Pro-Thrombotic Markers in Antiphospholipid Antibody (aPL)-Positive Patients: Preliminary Results from an Open-Label Prospective Pilot Study. Arthritis Rheum 2011; 63: 283.

77. Cuadrado MJ, Lopez-Pedrera C, Aguirre A et al. Changes Operated in Protein Pattern of Monocytes from Patients with Antiphospholipid Syndrome Treated with Statins. Arthritis Rheum 2007; 56: S782.

78. Goldfine AB. Statins: is it really time to reassess benefits and risks? N Engl J Med 2012; 366: 1752–1755.

79. Rand JH, Wu X, Quicnn AS et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-β2-glycoprotein I complexes to phospholipid bilayers. Blood 2008; 112: 1687–1695.

80. Rand JH, Wu X, Quinn AS et al. Hydroxycholoquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 2010; 115: 2292–2299.

81. Ruiz-Irastorza G, Egurbide MV, Pijoan JI et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythrmatosus. Lupus 2006; 15: 577–583.

82. Erkan D, Yazici Y, Peterson MG et al. A cross-sectional study of clinical risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology 2002; 41: 924–929.

83. Erre GL, Pardini S, Faedda R et al. Effect of rituximab on clinical a laborator features of antiphospholipid syndrome: a case report and rewiev of literature. Lupus 2008; 17: 50–55.

84. Mehdi AA, Uthman I, Khamashta M. Anti­phospholipid syndrome: pathogenesis and a windouw of treatment opportunities in the future. Eur J Clin Invest 2010: 40: 451–464.

85. Schulman S, Kearon C, Kakkar AK et al. RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342–2352.

86. The EINSTEIN Investigators. Oral Rivaroxaban for Symptomatic Venous Thromboembolism. N Engl J Med 2010; 363: 2499–2510.

87. Cohen H, Machin SJ. Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants? Lupus 2010: 19: 486–491.